\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Efficacy and safety of Mirabegron plus Solifenacin combination therapy
in comparison with Solifenacin monotherapy in Overactive bladder: A
Systematic review and Meta-analysis}



\author[1]{Sandesh Warudkar}%
\author[2]{Amit Jain}%
\author[2]{Nilanj Dave}%
\author[2]{Alok Chaturvedi}%
\affil[1]{Affiliation not available}%
\affil[2]{Intas Pharmaceuticals Ltd}%


\vspace{-1em}



  
  \date{May 28, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
Abstract: Introduction \& Objectives Antimuscarinic agents represent the
cornerstone of pharmacotherapy for Overactive bladder (OAB) but
persistence with treatment is often limited by undesirable side effects.
The purpose of this review was to evaluate the efficacy and safety of
combination therapy of mirabegron 50 mg and solifenacin 5 mg in
comparison with 5 mg and 10 mg of solifenacin monotherapy in patients
with OAB. Materials \& Methods An electronic database search was carried
out in Evidence Based Medicine Reviews, Cochrane Library and PubMed
using keywords Mirabegron, Solifenacin, Combination, Overactive bladder
based on the Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) guideline to include relevant randomized
controlled trials (RCT)s. The meta-analysis was performed by Review
Manager 5.4 software. Results Out of 907 studies screened, 4 RCTs
involving a total of 5339 patients were eligible for analysis. In
comparison to Solifenacin 5 and 10 mg monotherapy, combination therapy
resulted in significantly more improvement in mean volume voided (MVV)
per micturition, frequency of micturitions/24h, number of incontinence
epi\selectlanguage{ngerman}¬sodes/24h. Compared to Solifenacin 5 mg monotherapy, combination
therapy was found to have overall acceptable tolerability profile in
terms of treatment-emergent adverse events (TEAEs), dry mouth,
constipation. Whereas when compared to Solifenacin 10 mg monotherapy,
combination therapy was found to be better tolerated for all studied
safety outcomes. Conclusions Combination therapy of mirabegron 50 mg and
solifenacin 5 mg leads to significantly greater improvement in OAB
symptoms and is better tolerated in comparison with solifenacin 10
monotherapy.%
\end{abstract}\selectlanguage{ngerman}%



\sloppy


\textbf{Hosted file}

\verb`Combination Meta-analysis V2 110.docx`  available at \url{https://authorea.com/users/739172/articles/712954-efficacy-and-safety-of-mirabegron-plus-solifenacin-combination-therapy-in-comparison-with-solifenacin-monotherapy-in-overactive-bladder-a-systematic-review-and-meta-analysis}

\selectlanguage{english}
\FloatBarrier
\end{document}

